By John Revill

ZURICH (Reuters) -Roche Chief Executive Thomas Schinecker and other senior executives from the Swiss pharmaceuticals industry will meet with the government on Monday to discuss the threat U.S. tariffs pose to the crucial export sector.

Washington has imposed a 39% tariff – among the steepest of any country targeted during President Donald Trump’s global trade reset – on goods such as watches and machinery imported from Switzerland. Swiss pharmaceuticals are currently not subject to that levy.

The pharma industry is, meanwhile, also awaiting the outcome of a Section 232 national security investigation that could result in tariffs on U.S. drug imports eventually reaching 250%.

PHARMACEUTICALS: MOST IMPORTANT SWISS EXPORT

In addition to Roche, Novartis and Sandoz will also

See Full Page